GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 2334-2334
    Abstract: Introduction While some prognostic factors such as chromosome or gene mutations in acute myeloid leukemia (AML) have been reported, the indication of allogeneic stem cell transplantation in first complete remission (CR) of AML patients is still controversial. Evaluation of minimal residual disease (MRD) during chemotherapy is considered as one of the predictive markers for the prognosis of AML patients. Detection of leukemia-specific chimeric genes by real-time quantitative polymerase chain reaction is the most sensitive method to quantify MRD. However, because over 50% of AML patients lack suitable leukemia-specific chimeric genes for the detection of MRD, other gene markers for assessing MRD are necessary for a greater proportion of AML patients. Wilms tumor gene 1 (WT1) mRNA transcript levels in peripheral blood have been reported as a suitable molecular marker of MRD for the prediction of relapse in most AML patients. In contrast, in acute lymphoblastic leukemia (ALL) patients, it remains to be elucidated whether early and/or deep reduction of tumor burden predicts a good prognosis in AML patients achieved CR. Aims In this study, we focused on the clinical relevance of the log reduction levels of WT1 mRNA transcript in bone marrow (BM) as MRD during chemotherapies, and also the association between WT1 mRNA transcript levels and outcomes in adult AML patients achieved CR. Patients and methods From 2007 to 2011, 48 AML patients who received chemotherapy at hospitals in our study group were enrolled in this study. Written informed consent was obtained from each patient before starting induction chemotherapy. We analyzed transcript levels of WT1 mRNA in BM at diagnosis, after induction therapy and after final consolidation therapy. WT1 mRNA levels were determined using the WT1 mRNA Assay Kit (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) and normalized with GAPGH. Result We analyzed the expression levels of WT1 mRNA in 48 patients at diagnosis. Quantification of WT1 mRNA expression in BM at diagnosis was associated with neither disease-free survival (DFS) nor overall survival (OS). Twenty-eight of 32 patients who achieved CR could be analyzed for the expression levels of WT1 mRNA in BM after induction therapy. Expression levels of WT1 mRNA in BM after induction therapy were not associated with DFS and OS. Log reduction levels of WT1 mRNA transcript in BM after induction therapy were associated with DFS (P=0.0066) and OS (P=0.0074). Twenty-three CR patients could be examined for the expression levels of WT1 mRNA in BM after final consolidation therapy. Expression levels of WT1 mRNA in BM after final consolidation therapy were not associated with DFS and OS. Log reduction levels of WT1 mRNA transcript in BM after final consolidation therapy were associated with DFS (P=0.015) and OS (P=0.012). We analyzed the effect of log scales of WT1 mRNA expression levels in BM at diagnosis and the impact of log reduction levels of WT1 expression in BM by multivariate analysis adjusting stepwise p-values. Factors were adjustment for age, sex, SCT in 1CR and chromosome. The log scales of WT1 mRNA expression levels in BM at diagnosis were not associated with DFS and OS. We used Wd/i_log and Wd/c_log to assess the value of reduction of tumor burden. Wd/i_log was defined as a log scale of WT1 mRNA transcript level in BM at diagnosis divided by that after induction therapy. Wd/c_log was defined as a log scale of WT1 mRNA transcript level in BM at diagnosis divided by that after final consolidation therapy. Wd/i_log and sex were associated with DFS and only Wd/i_log was associated with OS. Hazard ratios of Wd/i_log for DFS and OS were 0.37 (P=0.0031) and 0.34 (P=0.0035), respectively, by every shallow remission level in log scale. Wd/c_log was also associated with DFS and OS. Hazard ratios for DFS and OS were 0.48 (P=0.0012) and 0.41 (P=0.022), respectively, by every shallow remission level in log scale. Conclusion Log reduction levels of WT1 mRNA expression in BM after induction therapy are suitable predictive markers for DFS and OS in AML patients achieved CR. It is suggested that early treatment response is important for AML patients such as ALL patients. Furthermore, log reduction levels of WT1 mRNA expression in BM after final consolidation therapy may be a predictive marker of good prognosis in AML and may be useful for the decision to proceed with allogeneic stem cell transplantation. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 2677-2677
    Abstract: [Background] Chronic red blood cell transfusions, leading to iron overload, cause hepatic, cardiac, and endocrine dysfunction. It is very important to monitor body iron stores and to start optimal iron chelation therapy. Serum ferritin, which is widely used as a surrogate marker of body iron stores, elevate under inflammation or liver injury. Therefore, reliable techniques to evaluate body iron stores are needed. The liver iro n concentration (LIC) is thought to be an indicator of total body iron stores and measurement of the T2* value by MRI has been a standard noninvasive technique to evaluate LIC. It should be worthwhile using CT, which is lower cost and widely applied in clinical setting. Dual-energy CT (DECT) is a technique to obtain additional information regarding tissue composition compared with what single-energy CT can provide. This technique is based on the fact that substances show different densities by two different energies. However, the role of DECT in monitoring LIC remains to be clarified. We examined whether a DECT could be a new technique for the measurement of LIC. [Patients and Methods] Eight transfusion-dependent patients underwent DECT. Patient 1 was a 54-year-old male with MDS (RCMD-RS). He received 66 U red blood cell transfusions in our hospital, and depended on transfusion in another hospital, but the total doses were not available. Patient 2 was a 37-year-old male with AML in 2nd relapse. His total red blood cell transfusions were 54 U. Patient 3 was a 66-year-old female with AML with MRC in 1st CR. She received 37 U red blood cell transfusions in our hospital, and depended on transfusion in another hospital, but total doses were not available. Patient 4 was a 47-year-old female who had received renal transplantation for chronic renal failure. She received 12 U red blood cell transfusions in our hospital, and had a long history of transfusion dependence in another hospital, but total doses were not available. Patient 5 was a 57-year-old male with MDS (RCMD). His total red blood cell transfusions were 148 U, and he received iron chelation therapy. Patient 6 was a 65-year-old male with AML with MRC. His total red blood cell transfusions were 82 U, and he received iron chelation therapy. Patient 7 was a 47-year-old male with AML in 3rd CR. He received 28 U red blood cell transfusions in our hospital, and depended on transfusion in another hospital, but total doses were not available. Patient 8 was a 52-year-old female with AA. Her total blood cell transfusions were 92 U. [Results] All patients were examined for serum ferritin and patients 1, 3, 4, 6, 7, and 8 also underwent liver MRI. Serum ferritin levels of patients 1, 3, 4, 6, 7, and 8 were 961, 2168, 7875, 795, 1921, and 5104 ng/ml, respectively. These patients showed hypointensity on MRI T2*-weighted images, and also showed liver iron deposition by DECT. Serum ferritin of patient 5 was 4042 ng/ml, and he showed liver iron deposition by DECT. Serum ferritin of patient 2 was 6113 ng/ml, and he did not show liver iron deposition by DECT. [Conclusion] Our results suggest that liver DECT could visualize liver iron deposition of transfusion-dependent patients and could be a new technique for the measurement of LIC instead of MRI. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 5463-5463
    Abstract: After allogeneic hematopoietic stem cell transplantation (HSCT), immune recovery is important to protect the patient from relapse and co-morbidities such as graft-versus-host disease (GVHD) and infection. Various numbers of low-frequency immunocompetent cells are known to exist among T cells and each subset shows different immunological action. Among them, γδ T cells were reported to facilitate a graft-versus-leukemia (GVL) effect and regulatory T cells (Tregs) were reported to prevent acute GVHD. In this study, we focused on the clinical relevance of γδ T cells and Tregs in peripheral blood (PB) after allogeneic HSCT in patients with hematological neoplasm to outcome. We retrospectively analyzed 33 adult patients with hematological neoplasms who underwent allogeneic HSCT between July 2011 and February 2015 at Niigata University Medical and Dental Hospital, including 17 with acute myeloid leukemia, 8 with acute lymphoblastic leukemia, 4 with myelodysplastic syndromes, 2 with Epstein-Barr virus-associated lymphoproliferative disorder, 1 with adult T-cell leukemia/lymphoma and 1 with primary myelofibrosis. Circulating γδ T cells and Tregs were analyzed by flow cytometry within 30-100 days after allogeneic HSCT. γδ T cells were identified as CD3+/γδTCR+ cells. Tregs were identified as CD4+/Foxp3+/CD25+ cells. The percentage of γδ T cells was calculated by dividing by CD3+ cells. The percentage of Tregs was calculated by dividing by CD4+ cells. The Kaplan-Meier method was used to estimate the probability of disease-free survival (DFS). The Mann-Whitney U test was used to compare the percentage of γδ T cells in PB or Tregs in PB and any grade of acute GVHD or grade II-IV acute GVHD. Cumulative relapse rate and non-relapse mortality (NRM) were based on Gray's estimates. Fine-Gray proportional hazards models were used for assessment by multivariate analysis of relapse rate. Factor adjustment was performed for age, conditioning regimen, disease status and HLA compatibility. The median percentage of γδ T cells divided by CD3+ cells in PB was 3.3% (0-28.4%). The median percentage of Tregs divided by CD4+ cells in PB was 1.9% (0-17.3%). The percentage of γδ T cells in PB was not associated with the incidence of acute GVHD. In addition, the percentage of Tregs in PB was not associated with the incidence of acute GVHD. Next, we established an immune scoring system according to the percentage of γδ T cells and Tregs in PB. Less than 4% of γδ T cells as a proportion of CD3+ cells in PB was scored as 1 point and more than 4% of Tregs as a proportion of CD4+ cells in PB was scored as 1 point. The patients with 1 point for γδ T cells did not show a significant difference to the patients with 0 points in terms of cumulative relapse rate or NRM. In addition, the patients with 1 point for Tregs did not show a significant difference to the patients with 0 points in terms of cumulative relapse rate or NRM. We classified the patients into score 0-1 and score 2 upon adding the points. Patients with score 2 showed a higher relapse rate in univariate analysis (p=0.002) and multivariate analysis (hazard ratio 3.65, p=0.017) than patients with score 0-1. Moreover, patients with score 2 showed higher DFS in univariate analysis (p=0.001) and multivariate analysis (hazard ratio 3.50, p=0.027) than patients with score 0-1. Our study suggests that the combination of a low rate of γδ T cells and a high rate of Tregs in PB after allogeneic HSCT is a poor prognostic factor for patients with hematological neoplasm. In addition, it suggests that the balance of immunosuppression and immunoactivation may be important for the outcome of patients after allogeneic HSCT. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 1445-1445
    Abstract: Background: Diffuse large B-cell lymphoma, not other specified (DLBCL, NOS) is the most common type of malignant lymphoma and accounts for approximately one-third of all non-Hodgkin lymphomas. Translocation of MYC, BCL2, and BCL6 genes detected by fluorescence in-situ hybridization (FISH) were found in approximately 10%, 14%, and 20% DLBCL, respectively. MYC translocation is already reported to be an independent poor prognostic factor in DLBCL. Immunohistochemical(IHC) analysis has revealed that concurrent protein expression of MYC and BCL2 could be a predictive factor for overall survival (OS). However, the relationship between translocation and expression of MYC, BCL2 and BCL6 is still unknown, and it is not clear what proportion of MYC and BCL2 IHC is predictive for OS. Objectives: The purpose of this study was to clarify the clinical prognostic value of immunostaining and chromosomal translocation of MYC, BCL2 and BCL6 among the populations in whom these results were investigated. Patients and Methods: Sixty-one adult patients, newly diagnosed as DLBCL, NOS between October 2003 and October 2012 at Niigata University Hospital, were analyzed retrospectively. MYC, BCL2 and BCL6 rearrangements were detected by FISH, and the expression of MYC, BCL2, and BCL6 proteins were investigated by IHC. To assess the proportion of these proteins, we created a tissue microarray (TMA). The median age was 62 years (range: 17-85 years), and the median follow up period was 42 months (range: 2-127 months). All patients were treated with R-CHOP or R-CHOP-like regimens. OS was estimated by the Kaplan-Meier method. Multivariate Cox regression for OS was used to identify the independent prognostic factors. Results: According to univariate analysis, MYC rearrangement (10%) was a prognostic factor (P = 0.026); however, BCL2 and BCL6 translocation were not prognostic indicators (11%, P = 0.899; 13%, P = 0.819, respectively). On the other hand, the expression of MYC detected by IHC showed no statistical significance for OS, even if the cut-off level by MYC and BCL6 immunostaining was modified. However, if we divided the patients into two groups, i.e., those with 0-9% and those with ≥10% expression of BCL2 immunostaining, ≥10% expression of BCL2 may be a prognostic factor (P = 0.0087). We subsequently analyzed whether the concurrent expression of MYC and BCL2 or that of MYC and BCL6 would be prognostic factors for OS. In this study, patients with ≥30% expression of MYC and ≥30% expression of BCL2 showed poor prognosis compared to other patients (P = 0.00234, 5-year OS 42%, 84% respectively). Furthermore, we divided the patients in two groups i.e., the germinal center B-cell-like (GCB) type and non-GCB type as described by Hans et al., and the non-GCB type was observed to be a poor prognostic factor in both groups (P = 0.013). Further, we investigated whether these factors could be independent factors for OS. Multivariate analysis revealed IPI3-5 (HR, 3.1510 [range: 1.181-3.151), P = 0.022), MYC translocation (HR, 3.686 [range: 1.113-12.210], P = 0.033), and MYC (≥30%)/BCL2 (≥30%) double-expression (HR, 4.051 [range: 1.447-11.340] , P = 0.0078) were independent poor prognostic indicators in newly diagnosed DLBCL patients treated with R-CHOP or R-CHOP like regimens. Conclusions MYC translocation by FISH and MYC (≥30%)/BCL2 (≥30%) double-expression detected by IHC could be independent prognostic factors for OS. However, MYC expression is not a surrogate marker for MYC translocation by FISH. In conclusion, FISH analysis of MYC translocation and MYC and BCL2 co-expression are important for predicting the prognosis of DLBCL. These results indicate that further validation is required using another population. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Internal Medicine, Japanese Society of Internal Medicine, Vol. 54, No. 6 ( 2015), p. 657-661
    Type of Medium: Online Resource
    ISSN: 0918-2918 , 1349-7235
    RVK:
    Language: English
    Publisher: Japanese Society of Internal Medicine
    Publication Date: 2015
    detail.hit.zdb_id: 2202453-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 96, No. 36 ( 2017-09), p. e7975-
    Type of Medium: Online Resource
    ISSN: 0025-7974
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2017
    detail.hit.zdb_id: 2049818-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Journal of Clinical and Experimental Hematopathology, Japanese Society for Lymphoreticular Tissue Research, Vol. 58, No. 4 ( 2018), p. 161-165
    Type of Medium: Online Resource
    ISSN: 1346-4280 , 1880-9952
    Language: English
    Publisher: Japanese Society for Lymphoreticular Tissue Research
    Publication Date: 2018
    detail.hit.zdb_id: 2395568-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Journal of Clinical and Experimental Hematopathology, Japanese Society for Lymphoreticular Tissue Research, Vol. 61, No. 1 ( 2021), p. 42-47
    Type of Medium: Online Resource
    ISSN: 1346-4280 , 1880-9952
    Language: English
    Publisher: Japanese Society for Lymphoreticular Tissue Research
    Publication Date: 2021
    detail.hit.zdb_id: 2395568-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Journal of Clinical and Experimental Hematopathology, Japanese Society for Lymphoreticular Tissue Research, Vol. 59, No. 1 ( 2019), p. 22-28
    Type of Medium: Online Resource
    ISSN: 1346-4280 , 1880-9952
    Language: English
    Publisher: Japanese Society for Lymphoreticular Tissue Research
    Publication Date: 2019
    detail.hit.zdb_id: 2395568-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Internal Medicine, Japanese Society of Internal Medicine, Vol. 52, No. 11 ( 2013), p. 1239-1242
    Type of Medium: Online Resource
    ISSN: 0918-2918 , 1349-7235
    RVK:
    Language: English
    Publisher: Japanese Society of Internal Medicine
    Publication Date: 2013
    detail.hit.zdb_id: 2202453-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...